Details of the Drug

General Information of Drug (ID: DMN3D72)

Drug Name

SL-172154

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Recombinant protein

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Inhibitor	[2]
Leukocyte surface antigen CD47 (CD47)	TT28S46	CD47_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Ovarian cancer

ICD Disease Classification

2C73

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
CD40L receptor (CD40)	DTT	CD40	4.61E-01	0.56	0.5

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04406623) Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Shattuck Labs.